Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:15 AM ET 10-Q
Financial Results Lifecore Biomedical, Inc. \De\ LFCR

Lifecore Biomedical, Inc. \De\ Q3 2026 Results: Net Loss of $40.1M, Loss Widens

Lifecore Biomedical reported a significant net loss of $61.2 million for the nine months ended September 30, 2026, compared to a $20.9 million loss in the prior year, primarily driven by a $35.6 million non-cash change in the fair value of a related party debt derivative. Total revenues decreased to $82.7 million from $105.7 million year-over-year, and the company recently entered into a merger agreement with affiliates of Webster Equity Partners.

Key figure
Net loss $40.1M
7:14 AM ET 8-K
Financial Results Lifecore Biomedical, Inc. \De\ LFCR

Lifecore Biomedical, Inc. \De\ Financial Results

Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.

Term
Q3 2026

“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”

Paul Josephs, president and chief executive officer of Lifecore
7:14 AM ET 8-K
Financial Results SelectQuote, Inc. SLQT

SelectQuote Financial Results

SelectQuote reported first quarter fiscal 2027 revenue of $280.0 million and a net loss of $20.3 million, showing a year-over-year improvement in Adjusted EBITDA and operating cash flow. The company reaffirmed its full-year fiscal 2027 guidance, expecting revenue between $1.35 billion and $1.45 billion and operating cash flow exceeding $60 million.

Term
Q1 2027

“We are proud of another strong quarter across both our Senior and Healthcare Services segments, resulting in a material year-over-year improvement in adjusted EBITDA and operating cash flow. We have high confidence in our current and long-term strategy to drive value for stakeholders, and we are pleased to reiterate our full-year financial targets for fiscal 2027.”

Tim Danker, SelectQuote’s Chief Executive Officer

“SelectQuote’s performance, in our seasonally slowest quarter, showcases the continued impact of our strategy to optimize profitability and cash flow. Despite lower revenue across both Senior and Healthcare Services, SelectQuote drove a 30% improvement in our year-over-year trailing twelve month adjusted EBITDA, and we remain on track to drive over $60 million in operating cash flow in fiscal 2027.”

Tim Danker, SelectQuote’s Chief Executive Officer
7:13 AM ET 10-Q
Financial Results Fiserv Inc FISV

Fiserv Q3 2026 Results: Net Loss of $5.94B

Fiserv Inc. reported a significant net loss of $5.94 billion for the third quarter of 2026, primarily driven by a $6.45 billion non-cash goodwill impairment charge. Total revenue for the quarter decreased slightly to $5.20 billion compared to $5.26 billion in the prior year period, while operating cash flow for the first nine months of the year remained positive at $3.09 billion.

Key figure
Net loss $5.94B
7:13 AM ET 8-K
Financial Results Rapport Therapeutics, Inc. RAPP

Rapport Therapeutics Financial Results

Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.

Term
Q3 2026

“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”

Abraham N. Ceesay, chief executive officer of Rapport
7:13 AM ET 8-K
Financial Results Geron Corp GERN

Geron Financial Results

Geron Corporation reported third quarter 2026 financial results, highlighted by $60.1 million in RYTELO net product revenue, a 5% increase over the prior quarter. The company reiterated its full-year RYTELO revenue guidance at the mid-to-high end of $220-$240 million and initiated a gated commercial launch in Europe, with availability expected in Germany by year-end.

Term
Q3 2026

“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”

Harout Semerjian, President and Chief Executive Officer of Geron
7:12 AM ET 8-K
Financial Results Viridian Therapeutics, Inc.\DE VRDN

Viridian Therapeutics, Inc.\DE Financial Results

Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.

“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”

Steve Mahoney, President and Chief Executive Officer
7:12 AM ET 8-K
Financial Results Datadog, Inc. DDOG

Datadog Financial Results

Datadog reported third quarter 2026 revenue of $1.20 billion, representing 35% year-over-year growth. The company achieved a non-GAAP operating margin of 28% and generated $251 million in free cash flow while expanding its large customer base to 4,860 clients with over $100k in ARR.

Term
Q3 2026

“Datadog delivered a strong third quarter, with 35% year-over-year revenue growth, $290 million in operating cash flow, and $251 million in free cash flow.”

Olivier Pomel, co-founder and CEO of Datadog

“We are innovating rapidly, including developing specialized AI models through our AI Research team, to help customers manage growing complexity and move towards autonomous operations.”

Olivier Pomel, co-founder and CEO of Datadog
7:11 AM ET 8-K
Financial Results Shoals Technologies Group, Inc. SHLS

Shoals Technologies Group Financial Results

Shoals Technologies Group reported Q3 2026 revenue of $195.3 million, a 43.8% increase year-over-year, driven by strong demand and market share capture. The company reported net income of $17.9 million and raised its full-year 2026 outlook following strong operational performance and the completion of its manufacturing facility transition.

Term
3 months

“We’re very pleased with our strong results in the period, as productivity improvements drove both quarterly revenue and Adjusted EBITDA above our expected range. We remain focused on making meaningful operational improvements as we finish 2026 on a strong note. The long-term health of the market remains robust and we’re well positioned to continue the momentum into 2027 and beyond.”

Brandon Moss, CEO of Shoals

“Our strategy is working — and the results prove it. With the move into our new facility complete, our focus today is on the customer; delivering quality solutions, on time, with market-leading customer service. With an unmatched market position, world-class manufacturing, and a breakthrough innovation pipeline, we are built for what's ahead and excited about the opportunities in front of us.”

Brandon Moss, CEO of Shoals
7:11 AM ET 8-K
Financial Results uniQure N.V. QURE

uniQure Financial Results

uniQure reported Q3 2026 financial results, highlighting a cash position of $768.4 million which is expected to fund operations into 2030. The company also announced that the FDA has granted Priority Review for its BLA for AMT-130 in Huntington’s disease with a PDUFA date of May 1, 2027.

“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease. We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”

Matthew Kapusta, chief executive officer at uniQure

“As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.”

Matthew Kapusta, chief executive officer at uniQure
7:09 AM ET 10-Q
Financial Results Pharmaceutical Resource Technology, Inc.

Pharmaceutical Resource Technology Q3 2026 Results: Turns Profitable, Net Income $455K

Pharmaceutical Resource Technology, Inc. reported a net profit of $132,975 for the nine-month period ended September 30, 2026, on revenues of $8.89 million. The company maintains a strong liquidity position with $5.15 million in cash and concluded that there is no substantial doubt regarding its ability to continue as a going concern.

Key figure
Net income $455K
7:08 AM ET 10-Q
Financial Results RYTHM, Inc. RYM

RYTHM Q3 2026 Results: Net Loss of $533K, Loss Narrows

RYTHM, Inc. reported a significant revenue increase to $60.2 million for the nine months ended September 30, 2026, compared to $6.6 million in the prior year, primarily driven by related party transactions. The company achieved a net income of $20.6 million for the period, largely due to a $26.8 million non-cash income tax benefit from the release of a valuation allowance.

Key figure
Net loss $533K
7:07 AM ET 8-K
Financial Results MoonLake Immunotherapeutics MLTX

MoonLake Immunotherapeutics Financial Results

MoonLake Immunotherapeutics reported Q3 2026 financial results and announced the submission of a Biologics License Application (BLA) to the FDA for sonelokimab in hidradenitis suppurativa. The company ended the quarter with $498.5 million in cash and equivalents, providing a projected cash runway into mid-2028.

Term
Q3 2026
7:07 AM ET 8-K
Financial Results CDW Corp CDW

CDW Financial Results

CDW Corporation reported third quarter 2026 financial results with net sales of $6.75 billion, a 17.7% increase year-over-year, driven by strong enterprise AI adoption and broad-based customer demand. The company also declared a quarterly cash dividend of $0.680 per share, payable on December 10, 2026.

“CDW delivered robust third quarter results, powered by broad-based strength across our diverse customer end-markets and strong momentum in enterprise AI adoption.”

Christine A. Leahy, chair and chief executive officer, CDW

“Strong customer demand and disciplined execution drove double-digit growth in gross profit, while operating leverage and capital management contributed to more than 20 percent growth in non-GAAP net income per diluted share.”

Albert J. Miralles, chief financial officer, CDW
7:07 AM ET 8-K
Financial Results Nuvectis Pharma, Inc. NVCT

Nuvectis Pharma Financial Results

Nuvectis Pharma reported third quarter 2026 financial results and provided a corporate update following its transformational in-licensing of ex-China rights to NXP100 and NXP200. The company ended the quarter with approximately $140 million in cash, providing a projected runway into the second half of 2029. Management is currently in discussions with the FDA regarding the U.S. regulatory path for ciprocopan (NXP100) in PNH and expects to provide an update by year-end.

“The last few months have been truly transformational for Nuvectis. The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis

“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
7:06 AM ET 8-K
Financial Results RYTHM, Inc. RYM

RYTHM Financial Results

RYTHM, Inc. reported third quarter 2026 revenue of $23.9 million, a 4% sequential increase, and a net loss of $0.5 million. The company highlighted significant growth in its THC beverage portfolio, reaching an annualized run rate of 320,000 cases and expanding retail availability to 8,000 doors across 18 states.

7:06 AM ET 10-Q
Financial Results CPI Card Group Inc. PMTS

CPI Card Group Q3 2026 Results: Net Income $5.02M, Up 117.5% YoY

CPI Card Group reported net income of $5.0 million for the third quarter of 2026, more than doubling the $2.3 million reported in the prior year period, driven by a 14.8% increase in revenue to $158.4 million. The company implemented a new segment structure in 2026, separating its proprietary technological solutions into a new Integrated Paytech segment following the acquisition of an on-premise instant issuance solution.

Key figure
Net income $5.02M · +117.5% YoY
7:06 AM ET 8-K
Financial Results Criteo S.A. CRTO

Criteo Financial Results

Criteo S.A. reported third quarter 2026 financial results with revenue of $416 million and net income of $6 million. The company highlighted the expansion of its Performance Connected TV capabilities into global markets and its ongoing advertising technology partnership with OpenAI.

“Despite near-term headwinds, we are making tangible progress across our business, with momentum in newer channels and a growing pipeline of opportunities. As we sharpen execution and operate with greater discipline, we remain focused on capturing the opportunities ahead and creating sustainable value for our shareholders.”

Michael Komasinski, Chief Executive Officer of Criteo
7:05 AM ET 8-K
Financial Results Seres Therapeutics, Inc. MCRB

Seres Therapeutics Financial Results

Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.

Term
Q3 2026

“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”

Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres

“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”

Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
7:05 AM ET 10-Q
Financial Results Brinks Co BCO ▶ Call

Brinks Q3 2027 Results

For the nine months ended September 30, 2026, Brink's reported revenues of $4,142.0 million, a 6.7% increase over the prior year, though net income attributable to the company decreased from $131.6 million to $91.0 million. The company experienced higher operating costs and a significant $62.4 million cash derecognition following the deconsolidation of its Malaysia business.

7:05 AM ET 8-K
Financial Results Charles River Laboratories International, Inc. CRL

Charles River Laboratories International Financial Results

Charles River Laboratories reported Q3 2026 revenue of $982.7 million and organic revenue growth of 4.7%, marking its second consecutive quarter of organic growth. The company increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by outperformance in its Discovery and Safety Assessment (DSA) segment.

Term
Q3 2026

“Our third-quarter results were highlighted by a return to organic revenue growth for the second consecutive quarter and significant margin expansion, which drove non-GAAP earnings per share growth of 27%. We were pleased with the performance of our DSA and Manufacturing segments, which both delivered organic revenue growth and improved profitability.”

James C. Foster, Chairman, President and Chief Executive Officer
7:05 AM ET 8-K
Financial Results Wayfair Inc. W

Wayfair Financial Results

Wayfair reported third quarter 2026 net revenue of $3.4 billion, a 9.7% increase year-over-year, driven by 11.4% growth in its U.S. business. The company achieved net income of $62 million and grew its active customer base by 4.7% to 22.2 million, signaling structural market share gains in a flat category.

Term
Q3 2026

“Q3 was our strongest quarter of growth in the post-pandemic period, with total net revenue up 9.7% year-over-year and our U.S. business growing over 11%. That growth flowed through nicely to the bottom line, with an Adjusted EBITDA Margin of 6.9%, our best Q3 result since 2020.”

Niraj Shah, CEO, co-founder and co-chairman, Wayfair

“At the start of this year, we told you we expected to take share in the U.S. at a pace we had not seen in several years. With U.S. revenue growing double digits against a roughly flat category here in Q3, we've done exactly that. That growth was driven by orders, which were up 12% year-over-year, and active customers up more than 4%. The momentum we have on orders and customers give us confidence that our share gains are structural, and we are still in the early innings.”

Niraj Shah, CEO, co-founder and co-chairman, Wayfair
7:05 AM ET 8-K
Financial Results Trimble Inc. TRMB

Trimble Financial Results

Trimble Inc. reported third quarter 2026 revenue of $966.8 million, up 7% year-over-year, and record annualized recurring revenue (ARR) of $2.56 billion. The company exceeded expectations for the quarter and updated its full-year 2026 guidance, reflecting solid execution of its Connect & Scale strategy.

Term
Q3 2026

“Our third quarter results surpassed expectations on both revenue and earnings per share, while delivering record annualized recurring revenue of $2.56 billion. Our full year 2026 guidance reflects solid execution against our Connect & Scale strategy, which continues to leverage our unique presence across the physical and digital worlds with our unmatched breadth and depth of connected industry data.”

Rob Painter, President and CEO of Trimble
7:05 AM ET 8-K
Financial Results Solaredge Technologies, Inc. SEDG

Solaredge Technologies Financial Results

SolarEdge Technologies reported Q3 2026 revenue of $326.1 million, meeting the midpoint of its guidance despite a 4.1% year-over-year decline. The company achieved its fifth consecutive quarter of positive free cash flow at $7.8 million and is implementing cost-reduction measures to address softer demand and reduced Q4 expectations.

Term
Q3 2026

“The SolarEdge team delivered third-quarter revenue of $326.1 million, at the midpoint of our guidance, with profitability in line with expectations. As near-term market uncertainty persists and given reduced revenue expectations for the fourth quarter, we are taking decisive steps to reduce costs, sharpen our focus, and support profitability amid softer demand.”

Shuki Nir, CEO of SolarEdge
7:04 AM ET 8-K
Financial Results Q32 Bio Inc. QTTB

Q32 Bio Financial Results

Q32 Bio reported third quarter 2026 financial results and provided a corporate update, including clinical data from its SIGNAL-AA trial of bempikibart. The company ended the quarter with $289.6 million in cash, which is expected to fund operations through Phase 3 topline results. Management plans to initiate a registration-directed program for bempikibart in severe alopecia areata in the first half of 2027.

Term
Q3 2026

“The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing”

Jodie Morrison, Chief Executive Officer of Q32 Bio

“We believe our data demonstrates the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata. We are pleased to welcome José and Ellie to lead the advancement of bempikibart into late-stage development and have made key senior appointments spanning clinical operations, clinical strategy and medical affairs, and regulatory affairs.”

Jodie Morrison, Chief Executive Officer of Q32 Bio
7:04 AM ET 10-Q
Financial Results Option Care Health, Inc. OPCH

Option Care Health Q3 2026 Results: Net Income $57.4M, Up 10.8% YoY

Option Care Health reported net revenue of $1.49 billion for the third quarter of 2026, a 4.1% increase over the prior year, with net income rising to $57.4 million. The company significantly improved its operating cash flow to $286.2 million for the first nine months of 2026, while continuing to execute its share repurchase program, spending $170.5 million on treasury stock.

Key figure
Net income $57.4M · +10.8% YoY
7:04 AM ET 8-K
Financial Results New York Times Co NYT

New York Times Financial Results

The New York Times Company reported third-quarter 2026 results, highlighted by a 14.6% increase in digital-only subscription revenues and the addition of 420,000 net digital-only subscribers. Total revenues rose 9.7% to $768.5 million, while adjusted operating profit grew 13.9% to $149.6 million, reflecting strong marketer demand and subscriber retention.

Term
Q3 2026

“Q3 was another quarter of strong execution and sustained momentum across The Times. Our results highlighted the enduring advantages of our strategy and our multi-revenue stream model. Subscriber growth was powered by strong engagement and retention across our portfolio. We grew operating profit and generated healthy free cash flow while continuing to invest in growth areas like video. As the information ecosystem continues to evolve, our essential subscription strategy — which is about human-made journalism and product experiences that people seek out directly and make room for in their lives — provides powerful advantages that we believe will only deepen with time.”

Meredith Kopit Levien, president and chief executive officer, The New York Times Company
7:03 AM ET 8-K
Financial Results Biocryst Pharmaceuticals Inc BCRX

Biocryst Pharmaceuticals Financial Results

BioCryst reported Q3 2026 total net revenue of $180.3 million, driven by $174.8 million in ORLADEYO sales, and achieved an operating profit of $53.3 million. The company increased its full-year total revenue guidance to $715-$730 million and highlighted the recent FDA approval of ORLADEYO oral pellets for patients aged 12 and older.

Term
3 years

“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success.”

Charlie Gayer, President and Chief Executive Officer

“This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders.”

Charlie Gayer, President and Chief Executive Officer
7:03 AM ET 8-K
Financial Results SharkNinja, Inc. SN

SharkNinja Financial Results

SharkNinja reported third quarter 2026 net sales of $1.98 billion, a 21.2% increase year-over-year, driven by strong performance in Cooking and Beverage Appliances and International markets. Net income rose 79.3% to $338.4 million, and the company raised its full-year 2026 outlook based on strong operational performance and innovation across its product categories.

Term
Q3 2026

“Q3 net sales grew 21.2%, marking our second consecutive quarter above 20% and our 14th consecutive quarter of double-digit growth. Our topline strength was well balanced across Domestic and International, with tremendous performance across channels, categories, and geographies. We believe this reflects our evolution into a Consumer Technology company operating at hyperscale, which shows up in what we make, how we market and sell, how fast we learn, and how far we reach.”

Mark Barrocas, Chief Executive Officer
7:03 AM ET 8-K
Financial Results Brinks Co BCO

Brinks Financial Results

The Brink's Company reported third-quarter 2026 results with revenue of $1.375 billion, up 3% year-over-year, driven by strong organic growth in ATM Managed Services (AMS) and Digital Retail Solutions (DRS). The company also provided an update on its pending acquisition of NCR Atleos, which is now expected to close in early January 2027 following regulatory progress in the UK.

“We delivered a strong third quarter and continued to build real momentum in our strategic focus areas of AMS and DRS. Growth in these lines of business accelerated sequentially, even against a challenging economic backdrop in many of our larger markets. Adjusted EBITDA grew 8%, and margins expanded by 90 basis points year-over-year, powered by favorable revenue mix and strong pricing dynamics.”

Mark Eubanks, President and CEO

“We are making strong progress toward closing our acquisition of NCR Atleos. With increasing clarity and momentum on the regulatory front, including the recent developments with the CMA in the United Kingdom, we now expect to close the acquisition in early January 2027.”

Mark Eubanks, President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.